Literature DB >> 9717921

Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM).

R K Gherardi1, M Coquet, P Chérin, F J Authier, P Laforêt, L Bélec, D Figarella-Branger, J M Mussini, J F Pellissier, M Fardeau.   

Abstract

BACKGROUND: An unusual inflammatory myopathy characterised by an infiltration of non-epithelioid histiocytic cells has been recorded with increasing frequency in the past 5 years in France. We reassessed some of these cases.
METHODS: We did a retrospective analysis of 18 such cases seen in five myopathology centres between May, 1993, and December, 1997. The myopathological changes were reassessed at a clinopathology seminar.
FINDINGS: Detailed clinical information was available for 14 patients. The main presumptive diagnoses were polymyositis and polymyalgia rheumatica. Symptoms included myalgias in 12 patients, arthralgias in nine, muscle weakness in six, pronounced asthenia in five, and fever in four. Abnormal laboratory findings were occasionally observed, and included raised creatine kinase concentrations, increased erythrocyte sedimentation rate, and myopathic electromyography. Muscle biopsy showed infiltration of the subcutaneous tissue, epimysium, perimysium, and perifascicular endomysium by sheets of large macrophages, with a finely granular PAS-positive content. Also present were occasional CD8 T cells, and inconspicuous muscle-fibre damage. Epithelioid and giant cells, necrosis, and mitotic figures were not seen. The images were easily distinguishable from sarcoid myopathy and fasciitis-panniculitis syndromes. Whipple's disease, Mycobacterium avium intracellulare infection, and malakoplakia could not be confirmed. Ten patients were treated with various combinations of steroids and antibiotics; symptoms improved in eight patients, and stabilised in two.
INTERPRETATION: A new inflammatory muscle disorder of unknown cause, characterised by a distinctive pathological pattern of macrophagic myofasciitis, is emerging in France.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9717921     DOI: 10.1016/s0140-6736(98)02326-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Clinical, serologic and magnetic resonance imaging of 3 cases of inflammatory myopathy with abundant macrophages in the Japanese population.

Authors:  Shintaro Hara; Tomoko Henmi; Atsushi Kawakami; Keita Fujikawa; Hiroshi Mukae; Yuji Ishimatsu; Noriho Sakamoto; Tomoyuki Kakugawa; Kenzou Kaji; Manabu Fujimoto; Masataka Kuwana; Toshiaki Tsukada; Katsuya Satoh; Masakatsu Motomura; Mami Tamai; Hideki Nakamura; Hiroaki Ida; Tomayoshi Hayashi; Tomoki Origuchi; Katsumi Eguchi; Shigeru Kohno
Journal:  Rheumatol Int       Date:  2010-12-02       Impact factor: 2.631

2.  Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.

Authors:  David Gordon; Peter Kelley; Susanne Heinzel; Peter Cooper; Nikolai Petrovsky
Journal:  Vaccine       Date:  2014-09-27       Impact factor: 3.641

Review 3.  Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease.

Authors:  Eitan Israeli; Nancy Agmon-Levin; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

4.  Macrophagic myofasciitis: characterization and pathophysiology.

Authors:  R K Gherardi; F J Authier
Journal:  Lupus       Date:  2012-02       Impact factor: 2.911

Review 5.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  MEFV gene polymorphisms and TNFRSF1A mutation in patients with inflammatory myopathy with abundant macrophages.

Authors:  K Fujikawa; K Migita; Y Shigemitsu; M Umeda; F Nonaka; M Tamai; H Nakamura; A Mizokami; T Tsukada; T Origuchi; N Yonemitsu; M Yasunami; A Kawakami; K Eguchi
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

7.  FDG-PET/CT Brain Findings in a Patient With Macrophagic Myofasciitis.

Authors:  Axel Van Der Gucht; Mehdi Aoun-Sebaiti; Paul Kauv; Eric Guedj; Jessie Aouizerate; Antoine Verger; Romain K Gherardi; Anne-Catherine Bachoud-Levi; François-Jérôme Authier; Emmanuel Itti
Journal:  Nucl Med Mol Imaging       Date:  2015-09-23

8.  Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA.

Authors:  Josette Cadusseau; Nilusha Ragunathan-Thangarajah; Mathieu Surenaud; Sophie Hue; Francois-Jérôme Authier; Romain K Gherardi
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  [Macrophagic myofascitis vs atypical Whipple's disease].

Authors:  K Spengos; A Vontzalidis; S Vassilopoulou; P Manta
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

10.  Vacuolar myopathy in a dog resembling human sporadic inclusion body myositis.

Authors:  Jason King; Richard A LeCouteur; Monica Aleman; D Colette Williams; Peter F Moore; Ling T Guo; Andrew P Mizisin; G Diane Shelton
Journal:  Acta Neuropathol       Date:  2009-08-29       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.